about
Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)Data acquisition for the histoculture drug response assay in lung cancer.Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast CancerBRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.Novel eradicative high-dose rate brachytherapy for internal mammary lymph node metastasis from breast cancer.Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.Epigenetic regulation of ZEB1-RAB25/ESRP1 axis plays a critical role in phenylbutyrate treatment-resistant breast cancer.Increased expression of integrin alpha3beta1 in highly brain metastatic subclone of a human non-small cell lung cancer cell line.[A case of multidrug-resistant breast cancer associated with multiple hepatic and bone metastases for which cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy proved effective].[Weekly administration of gemcitabine in outpatient clinic for non-small cell lung cancer].[Histoculture drug response assay (HDRA) guided induction concurrent chemoradiotherapy for mediastinal node-positive non-small cell lung cancer].[Histoculture drug response assay guided concurrent chemoradiotherapy for lung metastasis from adrenocortical carcinoma--a case report].[Histoculture drug response assay for solitary fibrous tumor--a case report].[Anastrozole-resistant breast cancer responsive to exemestane--a case report].[Cut-off level of docetaxel, paclitaxel and gemcitabine in histoculture drug response assay for non-small cell lung cancer].Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer.Epigenetic silencing of HOPX contributes to cancer aggressiveness in breast cancer.Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015.In vitro evaluation of dose-response curve for paclitaxel in breast cancer.A case of serum CEA disappearance curve after resection of breast carcinoma.Time course of carcinoembryonic antigen after resection of lung cancer: a predictor of recurrence.[A case of liver metastasis of breast cancer responding to letrozole].[Determination of treatment strategies for a 43-year-old single woman with Stage IV breast cancer].The safety of concentrated trastuzumab in 100 ml of saline solution for administration to patients with HER2-positive breast cancer: a phase 1 study.[A case of facial nerve palsy induced by nab-paclitaxel].Q57133112Lymph node metastasis and high serum CEA are important prognostic factors in hormone receptor positive and HER2 negative breast cancer
P50
Q28551320-032E610A-A635-49CD-BFD4-A31ED3EB9EB3Q33270590-3AC92CC2-E4F6-4A46-947A-6BD8C6430986Q35898006-F8FC1893-DB5C-4E6C-A569-C8238EA1701FQ36217730-F58F23F0-C866-4054-8D41-551B79E1F7BFQ36473142-383AEB00-544D-44BB-B74D-97C29382812DQ36510947-E97E66B2-0F3E-4B39-8010-DEF3D6892D7FQ36738957-073E7E9C-EE67-4FD7-8526-09FA2D36D5C8Q40589741-07DF438C-56AA-46F2-A426-85CFB87E8303Q43120476-E48FAF78-38BC-40CA-99E5-2DE6BC097C7BQ44265958-16E54531-0045-4121-B222-8E3612388C03Q44334830-924C4CAF-DB63-4FDE-8FDB-107CBC657E83Q44815502-CCA14B84-5462-4832-A666-85D07D12C2F4Q45127193-009B563C-1465-4E26-991D-C7B0C05D9BC2Q45167416-0096ABBE-2834-41E1-B08E-1567B8484A49Q46619525-F076AEEB-AEA2-46AA-8AC1-D5288C75CEA0Q47359343-0D642E8A-588E-44F8-A6C2-AA16FC4F13BDQ48955272-0DD7ED42-2AE0-492D-835B-1D529074F776Q50948753-57EEE4B0-9B19-48D2-9607-7C6D61F7C975Q51901656-C2F97052-0B6B-46FC-AA78-701452A2DBC8Q51983984-4B90E835-B5CE-48CC-B1A0-C6F8AC89B75FQ52011430-36EF5B0E-9C4E-4048-B459-667F15D71A67Q53175175-6EE84726-8746-45A0-B46D-AFD91F817FD9Q53598163-F0B18EEF-A99E-4A82-8D98-BB74213C5AC4Q54316504-B46124E2-4B63-4DBD-AEE4-E6B4BD4D76D4Q54367781-34674F4F-57E1-4524-A3E6-A09A0F6CA11FQ57133112-5ED1311F-7EED-4F08-B4A7-C554AC7326E4Q58568604-BF6BF742-D8F4-48AA-BAA5-D29F0809C2AF
P50
name
Hirokazu Tanino
@en
Hirokazu Tanino
@nl
type
label
Hirokazu Tanino
@en
Hirokazu Tanino
@nl
prefLabel
Hirokazu Tanino
@en
Hirokazu Tanino
@nl